Advertisement

NTRA

Natera, Inc.

Healthcare · USD

Set alert

Price alert · NTRA

All alert types
414.30 USD -21.70 -4.98%
As of Oct 30, 2026 Extended hours 414.30 0.00%
Bid
413.98 × 2
Ask
414.16 × 2
408.32 Day range 431.26
182.65 52-week range 436.00
YTD
+80.85%
1 year
+114.42%
Open
425.55
Prev close
436.00
Mkt cap
59.72B
Vol
2.43M
Avg vol
1.52M
EPS
-1.35
P/E
0.00
Div yield
0.00%
More statistics
Low
408.32
High
431.26
Forward P/E
-2329.62
Beta
1.50
Short ratio
3.13
Inst. own
96.69%
Dividend
0.00
Ex-div date
Earnings
Nov 5, 2026
50-d avg
375.27
200-d avg
265.27
1y target
416.39

5D chart

Chart tools
Interval
NTRA five-day price chart400.0409.0418.1427.1436.2Oct 26Oct 27Oct 28Oct 29Oct 30

Key statistics

Market cap
59.72B
Enterprise value
61.99B
Trailing P/E
0.00
Forward P/E
-2329.62
PEG ratio
0.00
Price / sales
22.06
Price / book
32.67
EPS (TTM)
-1.35
Beta
1.50
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
-7.11%
Revenue (TTM)
2.71B
Revenue growth
37.70%
Free cash flow
104.03M
Total cash
1.09B
Total debt
238.49M
Return on equity
-12.54%
Shares outstanding
144.14M
Short % of float
4.18%
50-day average
375.27
200-day average
265.27

Analyst view

Consensus: strong buy

Strong buy
Price target (mean) 416.39 +0.5% upside
Target (low)
280.00
Target (mean)
416.39
Target (high)
500.00
Ratings (0m) 23 21 buy · 2 hold · 0 sell
  • Strong buy4
  • Buy17
  • Hold2
  • Sell0
  • Strong sell0

Next earnings

Nov 5, 2026

Expected Nov 5, 2026. Consensus EPS estimate -0.28026.

Earnings history

Financials — quick view

All financials
NTRA Revenue — quarterly 752.75M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
NTRA Net income — quarterly -66.97M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
NTRA EPS — quarterly -0.47
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

Earnings

NTRA recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 5, 2026Sep 30, 2026-0.28124———
Aug 6, 2026Jun 30, 2026-0.49394-0.47+0.02+4.85%
May 7, 2026Mar 31, 2026-0.54222-0.56-0.02-3.28%
Feb 26, 2026Dec 31, 2025-0.512070.35+0.86+168.35%
Nov 6, 2025Sep 30, 2025-0.38569-0.64-0.25-65.94%
Aug 7, 2025Jun 30, 2025-0.61546-0.74-0.12-20.24%

Upgrades / downgrades

NTRA analyst upgrades and downgrades
DateFirmActionFromTo
Oct 27, 2026BTIGmainBuyBuy
Oct 19, 2026Canaccord GenuitymainBuyBuy
Oct 14, 2026JP MorganmainOverweightOverweight
Oct 13, 2026Morgan StanleymainOverweightOverweight
Oct 13, 2026TD CowenmainBuyBuy
Oct 7, 2026BarclaysmainOverweightOverweight

About Natera, Inc.

Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test. The company also provides Panorama, a non-invasive prenatal test; Horizon, a carrier screening test; Fetal Focus, a single-gene NIPT, or sgNIPT, that screens for 21 single-gene inherited conditions; and Vistara, a single-gene NIPT, which screens for 25 single-gene conditions. In addition, it offers Anora, which tests and analyzes miscarriage tissue from women who have experienced one or more pregnancy losses; Empower, a hereditary cancer screening test; Prospera, a test to assess active rejection in patients who have undergone solid organ transplantation; Renasight, a kidney gene panel test; and Constellation software, a cloud-based distribution model. Further, the company provides NateraCore, a platform to support the patient and provider experience; phlebotomy services; and EMR integration services. The company serves independent laboratories, national and regional reference laboratories, medical centers and physician practices for its screening tests, research laboratories, and pharmaceutical companies through its direct sales force and laboratory distribution partners, as well as Constellation licensees under its cloud-based distribution model. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays for clinical and commercial use. The company was formerly known as Gene Security Network, LLC and changed its name to Natera, Inc. in January 2012. Natera, Inc. was founded in 2003 and is headquartered in Austin, Texas.

Sector
Healthcare
Industry
Diagnostics & Research
Country
United States
Website
natera.com

News

Your note

Sign in to keep a note on NTRA — it syncs with the Stock Master app.

Insider holders

NTRA insider holders
InsiderRelationLatest transactionDateShares held
BAYNES ROY DDirectorStock Award(Grant)Jun 25, 202620,158
BOTHA ROELOF FREDERICKDirectorStock Award(Grant)Jun 25, 20261,080,780
BROPHY MICHAEL BURKESChief Financial OfficerSaleAug 3, 202651,637
CHAPMAN STEVEN LEONARDChief Executive OfficerSaleOct 27, 202691,232
FESKO JOHNPresidentSaleAug 9, 2026197,257
HEALY JAMES IDirectorStock Award(Grant)Apr 24, 20251,596,540

Institution ownership

NTRA institution ownership
Holder% heldSharesValueReported
JPMORGAN CHASE & CO8.93%12,865,3465.33BJun 29, 2026
Blackrock Inc.7.57%10,914,6084.52BJun 29, 2026
Price (T.Rowe) Associates Inc6.26%9,021,8953.74BJun 29, 2026
Vanguard Capital Management LLC4.32%6,228,2162.58BJun 29, 2026
Vanguard Portfolio Management LLC4.01%5,782,6402.40BJun 29, 2026
FMR, LLC3.78%5,451,3962.26BJun 29, 2026

Fund ownership

NTRA fund ownership
Holder% heldSharesValueReported
JPMorgan Trust II-JPMorgan Large Cap Growth Fund3.85%5,550,9402.30BJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund3.00%4,320,3511.79BJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund2.16%3,119,4161.29BJun 29, 2026
Fidelity Contrafund1.41%2,028,432840.38MAug 30, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund1.25%1,799,359745.47MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund1.14%1,642,271680.39MJun 29, 2026
Advertisement